Two clinically de-risked topical assets, both with positive human data.
Human clinical data has been generated for both dermatology candidates. Current treatments for genital warts focus on removing the superficial external lesion rather than targeting the underlying viral infection, are surgical, topical or immune-modulating, and all destroy tissue.
There are no approved antiviral therapies for external genital warts, and average recurrence rates range from 30 to 70% within the first six months.
Positive Phase IIa — OKG-0501, topical cream
| Endpoint | Placebo | Active | p-value |
|---|---|---|---|
| Week 8 mean % lesion area loss (ITT) | 31% | 71% | 0.0007 |
| Week 8 mean % lesion area loss (PP) | 31% | 72% | 0.0012 |
| Loss of 80% or greater lesion area (ITT) | 34% | 60% | 0.0253 |
| 100% clearance, FDA-recommended endpoint (ITT) | 13.2% | 37.8% | 0.013 |
| 100% clearance, FDA-recommended endpoint (PP) | 14.3% | 41.2% | 0.012 |
Positive Phase IIa — OKG-0501, topical cream
